Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

B-cell maturation antigen (BCMA) is an attractive therapeutic target highly expressed on differentiated plasma cells in multiple myeloma and other B-cell malignancies. GSK2857916 (belantamab mafodotin, BLENREP) is a BCMA-targeting antibody–drug conjugate approved for the treatment of relapsed/refrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Montes de Oca, Rocio, Alavi, Alireza S., Vitali, Nick, Bhattacharya, Sabyasachi, Blackwell, Christina, Patel, Krupa, Seestaller-Wehr, Laura, Kaczynski, Heather, Shi, Hong, Dobrzynski, Eric, Obert, Leslie, Tsvetkov, Lyuben, Cooper, David C., Jackson, Heather, Bojczuk, Paul, Forveille, Sabrina, Kepp, Oliver, Sauvat, Allan, Kroemer, Guido, Creighton-Gutteridge, Mark, Yang, Jingsong, Hopson, Chris, Yanamandra, Niranjan, Shelton, Christopher, Mayes, Patrick, Opalinska, Joanna, Barnette, Mary, Srinivasan, Roopa, Smothers, James, Hoos, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398105/
https://www.ncbi.nlm.nih.gov/pubmed/34253590
http://dx.doi.org/10.1158/1535-7163.MCT-21-0035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398105/
https://www.ncbi.nlm.nih.gov/pubmed/34253590
http://dx.doi.org/10.1158/1535-7163.MCT-21-0035

Ejemplares similares